| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Dehydrotumulosic acid targets the glucocorticoid receptor (GR) as an agonist. It also acts as a phospholipase A2 inhibitor with an IC50 of 0.845 mM. The compound shows anti-inflammatory activity and has been studied for its effects on renal fibrosis and kidney function. As a triterpenoid from Poria cocos, it is involved in immunomodulation and exhibits dual antiviral and anti-inflammatory benefits. The compound's interaction with the glucocorticoid receptor is thought to mediate its anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Dehydrotumulosic acid exhibits phospholipase A2 inhibitory activity with an IC50 of 0.845 mM. The compound shows anti-inflammatory activity in various in vitro assays. It also exhibits antioxidant and nephroprotective effects. As a glucocorticoid receptor agonist, dehydrotumulosic acid has been shown to have effects that are more sustained than those of dexamethasone, highlighting its potential for dual antiviral and anti-inflammatory benefits. These in vitro activities support the compound's traditional use in Chinese herbal medicine.
|
| ln Vivo |
In vivo studies have demonstrated that Dehydrotumulosic acid is active in different models of acute and chronic inflammation. It significantly diminished mouse ear edema induced by ethyl phenylpropiolate. The compound has been shown to exert anti-inflammatory, antioxidant, and nephroprotective effects in vivo, particularly in regulating renal fibrosis and improving kidney function. These in vivo activities support the traditional use of Poria cocos for its pharmacological effects and suggest potential therapeutic applications for dehydrotumulosic acid in inflammatory and renal diseases.
|
| Enzyme Assay |
The in vitro enzyme assays for Dehydrotumulosic acid typically involve measuring its inhibition of phospholipase A2 activity. In these assays, the compound is incubated with phospholipase A2 and a suitable substrate, and the enzyme activity is measured using colorimetric or fluorometric detection methods. The IC50 value is calculated from dose-response curves. For glucocorticoid receptor binding assays, the compound's affinity for the receptor is measured using radioligand binding or cell-based reporter assays. These assays are standard for characterizing the compound's anti-inflammatory and enzyme inhibitory activities.
|
| Cell Assay |
Cellular assays for Dehydrotumulosic acid are conducted using various cell lines to assess its anti-inflammatory, antioxidant, and nephroprotective effects. Cells are treated with varying concentrations of the compound, and markers of inflammation, oxidative stress, and cell viability are measured. For anti-inflammatory studies, cells are stimulated with inflammatory agents, and cytokine production and NF-kappaB activation are assessed. For nephroprotective studies, kidney cells are exposed to nephrotoxic agents, and cell damage is assessed. These cell-based assays confirm the compound's biological activities and provide insights into its mechanism of action.
|
| Animal Protocol |
In vivo animal studies for Dehydrotumulosic acid are conducted in mouse and rat models of inflammation and renal disease. For anti-inflammatory studies, mouse ear edema induced by ethyl phenylpropiolate is used to assess the compound's ability to reduce inflammation. For nephroprotective studies, animal models of renal fibrosis are used, and kidney function and histopathology are assessed. The compound is administered orally or by injection at various doses, and efficacy is assessed by measuring biochemical markers, tissue histopathology, and functional outcomes. These studies confirm the compound's in vivo efficacy and support its potential therapeutic applications.
|
| ADME/Pharmacokinetics |
Dehydrotumulosic acid has a molecular weight of 484.71 and a molecular formula of C31H48O4. The compound appears as a white powder. For research use, dehydrotumulosic acid is typically stored as powder at -20degC for up to 3 years or at 4degC for up to 2 years. The compound is soluble in appropriate organic solvents for biochemical and cell-based assays. Detailed pharmacokinetic parameters such as oral bioavailability, half-life, and tissue distribution have not been determined for this compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for Dehydrotumulosic acid are limited. As a natural product from Poria cocos, which has a long history of traditional medicinal use, the compound is presumed to have a reasonable safety profile. Poria cocos has been consumed as a traditional medicine with no major safety concerns reported. However, the specific toxicity profile of purified dehydrotumulosic acid has not been systematically evaluated in preclinical studies. Standard toxicological assessments would be needed to establish the safety profile for any potential therapeutic applications.
|
| References | |
| Additional Infomation |
Reports indicate that dehydro-dehydro ...
Dehydrotumulosic acid (CAS#: 6754-16-1) is a triterpenoid from Poria cocos, a fungus used in Chinese herbal medicine. It has a molecular formula of C31H48O4 and a molecular weight of 484.71. The compound exhibits anti-inflammatory, antioxidant, and nephroprotective effects, acts as a glucocorticoid receptor agonist, and inhibits phospholipase A2 with an IC50 of 0.845 mM. Dehydrotumulosic acid is not approved for clinical use and is available only for research purposes in natural product chemistry and pharmacology. |
| Molecular Formula |
C31H48O4
|
|---|---|
| Molecular Weight |
484.7104
|
| Exact Mass |
484.355
|
| CAS # |
6754-16-1
|
| PubChem CID |
15225964
|
| Appearance |
White to off-white solid powder
|
| Density |
1.11±0.1 g/cm3
|
| Boiling Point |
621.7±55.0 °C
|
| Melting Point |
272-275°C
|
| LogP |
6.536
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
35
|
| Complexity |
957
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC(C)C(=C)CC[C@H]([C@H]1[C@@H](C[C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C)O)C(=O)O
|
| InChi Key |
LADJWZMBZBVBSB-YEXRKOARSA-N
|
| InChi Code |
InChI=1S/C31H48O4/c1-18(2)19(3)9-10-20(27(34)35)26-23(32)17-31(8)22-11-12-24-28(4,5)25(33)14-15-29(24,6)21(22)13-16-30(26,31)7/h11,13,18,20,23-26,32-33H,3,9-10,12,14-17H2,1-2,4-8H3,(H,34,35)/t20-,23-,24+,25+,26+,29-,30-,31+/m1/s1
|
| Chemical Name |
(2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~68.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0631 mL | 10.3154 mL | 20.6309 mL | |
| 5 mM | 0.4126 mL | 2.0631 mL | 4.1262 mL | |
| 10 mM | 0.2063 mL | 1.0315 mL | 2.0631 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
